Grant received in 2023
DCCC has funded 199.600 DKK to the project.
Only 90-100 Danes are diagnosed with peripheral T-cell lymphoma (PTCL) each year. As it is a rare form of cancer, international collaboration is a prerequisite for obtaining a sufficiently large patient base for a larger randomized clinical trial and ultimately, improving the prognosis for PTCL.
The applicants wish to prepare an investigator-initiated clinical study via a Nordic collaboration, where patients will be recruited for the protocol across Denmark, Norway, Sweden and Finland.
The study will, among other things, address whether ctDNA can be used to improve treatment response and early detection of relapse and whether biomarker-based maintenance therapy can reduce the risk of relapse. The funds from the DCCC will be used for study preparation activities, such as protocol writing, planning meetings and a boarding school.
Multidisciplinary organisation
Dansk Lymfom Gruppe (DLG) & The Nordic Lymphoma Group (NLG)
Project stakeholders
- Niels Pallisgaard, Professor, Zealand University Hospital
- Thomas Relander, Clinical Associate Professor, Lund University Cancer Center/Skåne University Hospital, Sweden
- Helle Toldbod, functional manager A-CTO, Aarhus University Hospital Louise Laursen, Scientific coordinator, Aarhus University Hospital
- Tarec El-Galaly, Clinical Professor, Aalborg University Hospital
- Thomas Stauff is Larsen, Clinical Associate Professor, Odense University Hospital
- Peter de Nully Brown, Clinical lecturer, Rigshospitalet
- Christian Bjørn Poulsen, Clinical Associate Professor, Zealand University Hospital
- Francesco Annibale d'Amore, Clinical chair professor, senior physician, DMSc, Aarhus University Hospital. Primary contact person, e-mail: frandamo@rm.dk
- The T-cell lymphoma working group under the Nordic Lymphoma Group (NLG)
- The committee for T-cell lymphomas under the Danish Lymphoma Group (DLG)